According to a survey by the Association of Pharmaceutical Industry Research (Interfarma), in the last seven years there has been a decreaseof 242 clinical trials, leading to a potential loss of R$ 490 million (£100 million).
One of the main obstacles may be the current time to approval by the National Agency of Sanitary Surveillance (ANVISA), which takes four times as long compared to the United States and South Korea (12 months vs. three months). As trials are conducted in parallel, the extra delay may result in loss of investment.
In addition, some requirements set out by the National Commission for Research Ethics (CONEP) makes choosing research within Brazil even more problematic. For example, researchers are required to follow-up on patients receiving treatment throughout their lifetime, whilst most other countries, by comparison, establish a monitoring period.
A 2015 Senate bill (PL 200) is currently in motion and aims to simplify processes, bringing them in line with more established countries.